Ginkgo Bioworks Holdings, Inc. 8-K Filing

TL;DR

Ginkgo Bioworks filed an 8-K on June 14th about shareholder votes from June 13th.

AI Summary

Ginkgo Bioworks Holdings, Inc. filed an 8-K on June 14, 2024, reporting on matters submitted to a vote of security holders on June 13, 2024. The filing details the company's corporate structure, including its incorporation in Delaware and its fiscal year end of December 31. It also lists former company names, Soaring Eagle Acquisition Corp. and Spinning Eagle Acquisition Corp., with their respective name change dates.

Why It Matters

This filing provides essential corporate information and updates regarding shareholder votes, which are crucial for understanding the company's governance and operational decisions.

Risk Assessment

Risk Level: low — This filing is primarily procedural and informational, detailing corporate structure and past name changes, with no immediate financial or operational risks indicated.

Key Players & Entities

• Ginkgo Bioworks Holdings, Inc. (company) — Registrant
• Soaring Eagle Acquisition Corp. (company) — Former company name
• Spinning Eagle Acquisition Corp. (company) — Former company name
• June 13, 2024 (date) — Date of earliest event reported
• June 14, 2024 (date) — Date of report

FAQ

Key Financial Figures

• $0.0001 — stered Class A common stock, par value $0.0001 per share DNA NYSE Warrants to purchas
• $11.50 — mon stock, each at an exercise price of $11.50 per share DNA.WS NYSE Indicate by che

Filing Documents

• dna-20240613.htm (8-K) — 47KB
• 0001628280-24-028287.txt ( ) — 212KB
• dna-20240613.xsd (EX-101.SCH) — 2KB
• dna-20240613_def.xml (EX-101.DEF) — 16KB
• dna-20240613_lab.xml (EX-101.LAB) — 28KB
• dna-20240613_pre.xml (EX-101.PRE) — 16KB
• dna-20240613_htm.xml (XML) — 4KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On June 13, 2024, Ginkgo Bioworks Holdings, Inc. (the "Company") held its 2024 annual meeting of shareholders (the "Annual Meeting"). A total of 1,374,218,617 shares of Class A common stock and 353,238,955 shares of Class B common stock were present or represented by proxy at the Annual Meeting, representing approximately 82.93% of shares of Class A common stock and Class B common stock, entitled to vote as a single class at the Annual Meeting, and representing approximately 92.33% of shares of Class B common stock entitled to vote as a separate class at the Annual Meeting. Each holder of Class A common stock was entitled to one (1) vote for each share held on all matters voted upon by holders of Class A common stock. Each holder of Class B common stock was entitled to ten (10) votes for each share held on all matters voted upon. The shareholders voted on the matters presented at the Annual Meeting, and the shares present, in person or by proxy, were voted as follows: 1. Election of directors Proposal one was the election of nine nominees to serve as directors of the Company, each until the next annual meeting of shareholders or until their successor shall have been elected and qualified. Holders of the Class B common stock, voting as a separate class, voted upon two nominees designated to be elected by the holders of Class B common stock. Holders of the Class A common stock and Class B common stock, voting together as a single class, voted upon seven nominees designated to be elected by the holders of Class A common stock and Class B common stock. The results of the vote were as follows: Director nominees designated to be elected by holders of Class B common stock: Nominee Votes For Votes Against Abstentions Broker Non-Votes Jason Kelly 3,516,796,470 6,103,930 9,489,150 N/A Reshma Shetty 3,516,486,800 5,359,790 10,542,960 N/A Director nominees designated to be elected by holders o

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GINKGO BIOWORKS HOLDINGS, INC. Date: June 14, 2024 By: /s/ Mark Dmytruk Name: Mark Dmytruk Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR